Legal DealFolio - Curetis AG Closing of Series B Financing Round

On 22 April 2013 Curetis AG announced the closing of a Series B financing round totalling 12.5 million euros. Lead investor in the amount of 6 million euros is HBM Biocapital II LP. The company's existing institutional investors aeris Capital, LSP Life Sciences Partners, Forbion Capital, BioMedInvest, Roche Venture Fund, CD Venture und KfW as well as private investors and management have also participated in this financing round, geared to the next phase of commercial and operational growth of Curetis AG. Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialisation of reliable, fast and cost-effective products for diagnosing severe infectious diseases. HBM Partners is a globally active, healthcare-focused investment management group headquartered in Switzerland. The funds advised by HBM invest in private and public companies across North America, Europe, India and China. Since 2001, HBM has generated more than 40 trade sales and IPOs of pharma/biotech, medtech and diagnostics companies. SJ Berwin advised HBM Biocapital on this transaction. Advice was provided by partner Jan Dirk Heerma und associate Olga Balandina-Luke (both Corporate, Berlin). The investment vehicle was set up by Alexandrine Armstrong-Cerfontaine (Luxembourg) and Christian Schatz (Munich, both Funds).

Deal Date:	25-04-2013	Practice Area:	Corporate and M&A
Deal Title:	Curetis AG Closing of Series B Financing Round	Industry:	Pharmaceuticals & Biotechnology
Description:	On 22 April 2013 Curetis AG announced the closing of a Series B financing round totalling 12.5 million euros. Lead investor in the amount of 6 million euros is HBM Biocapital II LP. The company's existing institutional investors aeris Capital, LSP Life Sciences Partners, Forbion Capital, BioMedInvest, Roche Venture Fund, CD Venture und KfW as well as private investors and management have also participated in this financing round, geared to the next phase of commercial and operational growth of Curetis AG. Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialisation of reliable, fast and cost-effective products for diagnosing severe infectious diseases. HBM Partners is a globally active, healthcare-focused investment management group headquartered in Switzerland. The funds advised by HBM invest in private and public companies across North America, Europe, India and China. Since 2001, HBM has generated more than 40 trade sales and IPOs of pharma/biotech, medtech and diagnostics companies. SJ Berwin advised HBM Biocapital on this transaction. Advice was provided by partner Jan Dirk Heerma und associate Olga Balandina-Luke (both Corporate, Berlin). The investment vehicle was set up by Alexandrine Armstrong-Cerfontaine (Luxembourg) and Christian Schatz (Munich, both Funds).
Financial Center:	Berlin	Value:	0.00-100.00
Advised Party:	Private Equity Investor	Law Firm	King & Wood Mallesons SJ Berwin
Target Company Jurisdiction	Germany	Acquiror Jurisdiction	Germany
Classification:	Financial Buyer Acquisitions Minority Investment	Lawyer	Jan Dirk Heerma

Practice Areas -

Corporate and M&A Law Firms and Lawyers

Practice Areas - Corporate and M&A Law Firms and Lawyers